Who are simvastatin and ezetimibe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosuvastatin and Ezetimibe, Atorvastatin, Ezetimibe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/simvastatin-and-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

simvastatin and ezetimibe — Competitive Intelligence Brief

simvastatin and ezetimibe (simvastatin and ezetimibe) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin and cholesterol absorption inhibitor combination. Area: Cardiovascular.

marketed Statin and cholesterol absorption inhibitor combination HMG-CoA reductase and NPC1L1 transporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

simvastatin and ezetimibe (simvastatin and ezetimibe) — UMC Utrecht. Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
simvastatin and ezetimibe TARGET	simvastatin and ezetimibe	UMC Utrecht	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase and NPC1L1 transporter
Rosuvastatin and Ezetimibe	Rosuvastatin and Ezetimibe	Hanmi Pharmaceutical Company Limited	marketed	Statin and ezetimibe combination	HMG-CoA reductase and NPC1L1 transporter
Atorvastatin, Ezetimibe	Atorvastatin, Ezetimibe	Abant Izzet Baysal University	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin and cholesterol absorption inhibitor combination class)

Abant Izzet Baysal University · 1 drug in this class
UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). simvastatin and ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/simvastatin-and-ezetimibe. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab